CO-CRYSTAL OF UPADACITINIB AND DIACETYL-D-TARTARIC ACID AND PROCESS FOR THE PREPARATION THEREOF FIELD OF THE INVENTION The present invention relates to a Co-crystal of Upadacitinib. More particularly, the present invention relates to a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further peaks additional at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. Upadacitinib Diacetyl-D-tartaric acid (DATA) BACKGROUND OF THE INVENTION Upadacitinib is the adopted name of drug compound having a chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]pyrazin-8- yl)-N-(2,2,2- trifluoroethyl)- pyrrolidine-l-carboxamide compound of Formula-Ia and structure as below. Formula-Ia Upadacitinib, also known as ABT-494, is potent and selective JAK inhibitor approved for rheumatoid arthritis (RA). Upadacitinib is approximately 74-fold selective for JAK1 over JAK2 in cellular assays dependent on specific, relevant cytokines. Upadacitinib demonstrates efficacy in rat arthritis models. Researchers found that the proportion of patients meeting the American College of Rheumatology 20 percent improvement criteria (ACR20) at week 12 was higher with Upadacitinib than placebo (62 to 80 percent versus 46 percent). Patients were randomized to receive immediate-release Upadacitinib at 3, 6, 12, or 18 mg twice daily or matching placebo. The researchers found that significantly more patients receiving Upadacitinib achieved an ACR20 response (53 to 71 percent) versus placebo (34 percent). Preliminary evidence suggests that compared to Tofacitinib, Upadacitinib may spare JAK2 and JAK3 dependent signaling. US RE47221 discloses a process for the preparation of Upadacitinib of Formula- Ia as illustrated in the Scheme-I below. First, the compound of Formula-II is deprotected in the presence of trifluoroacetic acid/HCl in 1,4-dioxane solvent to obtain compound of Formula-III, which is further reacted with benzyl-2,5- dioxopyrrolidine-1-yl-carbonate to obtain compound of Formula-IV followed by reaction with HBr/oxalyl chloride in the presence of trimethylsilyldiazomethane to obtain compound of Formula-V. Condensation of compound of Formula-V with compound of Formula-VI in the presence of NaH in DMF to obtain compound of Formula-VII, which further undergoes cyclization in the presence of dithaiophosphetane to obtain compound of Formula-VIII. Deprotection of compound of Formula-VIII in the presence of HBr to obtain compound of Formula- IX followed by reacting with 2,2,2-trifluoroethanamine in the presence of CDI in DMF to obtain compound of Formula-X. Further, deprotection of compound of Formula-X in the presence of sodium hydroxide followed by resolution using chiral preparative HPLC to obtain Upadacitinib of Formula-(Ia). The synthetic procedure is illustrated in Scheme-I as below: Oxalyl chloride/ THF/ 1,4-Dioxane/ Benzyl 2,5-dioxopyrrolidine- Trimethylsilyl- HCl 1-yl-carbonate diazomethane/HBr Step-I . HCl Step-II Step-III ( _II) ^(III) (IV) (V) NaH/DMF Step-IV (VI) HBr Dithaiophosphetane CDI/DMF Step-VI Step-VII Step-V ( _X) ^(IX) (VIII) Step-VIII 1. NaOH 2. Chiral preparative HPLC (VII) Upadacitinib of Formula-Ia Scheme-I US9951080 also discloses a process for the preparation of Upadacitinib of Formula- Ia as shown in Scheme II below, by the condensation of compound of Formula-Va with compound of Formula-VIa in the presence of lithium tert butoxide to obtain compound of Formula-VIIa, which undergoes cyclization in the presence of Trifluoroacetic anhydride (TFAA) in pyridine followed by deprotection in the presence of sodium hydroxide to obtain compound of Formula-XI. Further, deprotection of compound of Formula-XI in presence of HCl in EtOH/ EtOAc produces compound of Formula-XII. And, compound of Formula-XII is further reacted with 2,2,2-trifluoroethanamine in the presence of CDI, KOH and Dipotassium phosphate (K2HPO4) to obtain Upadactinib of Formula-Ia. The synthetic procedure is illustrated in Scheme-II as below: LiO ^t Bu 1. TFAA/ Pyridine D ^MA 2. NaOH Step-I Step-II (VIa) (IV) (Va) (XI) Step-III HCl/ EtOH/ EtOAc (VIIa) .2HCl CDI/ K2HPO4 Step-IV (XII) Upadacitinib (Formula-Ia) Scheme-II US 9951080 discloses various solid-state forms of upadacitinib free base such as Form- A (Isopropyl aetate/ water solvate), Form-B (hydrate), Form-C (Hemihydrate) and Form-D (Anhydrous) and different acid addition salts of upadacitinib were disclosed in US9951080. The described upadacitinib salts include a tartrate hydrate, various hydrochloride solvates designated Form AA, Form BB and Form CC as well as crystalline forms of L-Maleate salt designated Form AAA and Form BBB, respectively. Crystalline Form-C Hemihydrate of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 7.7, 7.9, 9.6, 10.3, 13.4, 13.9, 15.1, 15.5, 15.9, 17.0, 17.2, 17.8, 18.1, 18.3, 19.3, 19.7, 20.5, 20.9, 21.7, 21.9, 22.2, 23.5, 24.4, 24.9, 28.2 and 29.5° 2θ. US ‘ 080 further discloses that the peaks at 7.9, 10.3, 13.4, 15.1, 15.5, 17, 20.9 and 21.7 are major characteristic peaks for Crystalline Form-C Hemihydrate of Upadacitinib. Crystalline Form-D Anhydrous of Upadacitinib disclosed in US 9951080 is characterized by X-ray diffraction pattern (PXRD) comprising the peaks at 4.0, 8.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2θ. US ‘080 further discloses that the peaks at 4.0, 9.7, 14.2, 14.5, 19.0 and 20.3° 2θ. are major characteristic peaks for Crystalline Form-D anhydrous of Upadacitinib. US 20220002306 A1 discloses a Crystalline form CSI of Upadacitinib (acetic acid solvate). US 20210380596 A1 discloses a Crystalline Form-CSII of Upadacitinib (Anhydrate). EP 3891151 A1 discloses a Crystalline Phosphate salt of Upadacitinib. WO 2020115213 A1 discloses acetic acid solvate of Upadacitinib. CN 112110929 A1 discloses Crystalline Forms of CM-I and CM-II of Upadacitinib. CN 112409362 A1 discloses Crystalline Forms of Upadacitinib intermediate. US 20220041611 A1 discloses crystal form-A of the Di-p-toluoyl-L-tartrate of Upadacitinib, oxalate of Upadacitinib and PTSA salt of Upadacitinib. WO 2021/244323 A1 discloses Crystal form CSIV of Upadacitinib (Sebacic acid Co-crystal) and Crystal form CSV of Upadacitinib (Glutaric acid Co-crystal). US 20220204519 A discloses a Crystal form CSVI of Upadacitinib (Succinic acid Co-crystal) and Crystal form CSVII of Upadacitinib (Adipic acid Co-crystal). IN 202041025283 A discloses a crystalline Form-US of Upadacitinib and succinic acid (co-crystal). IN 202041052794 A discloses a Crystalline Form-UF of Upadacitinib and fumaric acid. The above prior art references disclose various polymorphic forms of Upadacitinib free base. None of the prior art discloses co-crystals of Upadacitinib and Diacetyl- D-tartaric acid (DATA). The inventors of the present invention have developed a novel co-crystal of Upadacitinib and Diacetyl-D-tartaric acid which is more stable and suitable for making formulation. SUMMARY OF THE INVENTION The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention further provides Co-crystal of Upadacitinib and Diacetyl-D- tartaric acid (DATA) characterized in that its powder X-ray powder diffraction pattern is basically the same as that of FIG.1. The present invention also provides a process for preparing the compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), Formula-I Diacetyl-D-tartaric acid (DATA) comprising the steps of: a) reacting compound of Formula-Va, Formula-Va with compound of Formula-VI Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII. Formula-XIII b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV. Formula-XIV c) deprotecting the compound of Formula-XIV in-situ in presence of an acid in a suitable solvent followed by treating with (+)-Di-p-toluoyl-D-tartaric Acid (DPTA) in an alcohol solvent to produce compound of Formula-XV. Formula-XV d) reacting the compound of Formula-XV with 2,2,2-trifluoroethanamine or it’s salt in presence of Carbonyldiimidazole (CDI) and a base in a suitable solvent to produce compound of Formula-XVI. Formula-XVI e) deprotecting the compound of Formula-XVI in presence of a base in a suitable solvent followed by treating with p-Toluenesulfonic acid to produce a compound of Formula-XVII. XVII f) treating the compound of Formula-XVII with Diacetyl-D-Tartaric acid in a suitable solvent followed by adding anti-solvent and precipitation the compound of Formula-I. DESCRIPTION OF THE DRAWINGS: Figure 1: Illustrates the Single Crystal X-ray Diffraction (SCXRD) diagram of compound of Formula-I which is a co-crystal of Upadacitinib and Diacetyl-D- tartaric acid (DATA). Figure 2: Illustrates the PXRD diagram of compound of Formula-I which is a co- crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA). DETAILED DESCRIPTION OF THE INVENTION The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1,7.4, 9.7, 10.6, 12.5, 14.3, 15.9, 16.5, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD) comprising the peaks at about 5.3, 6.1, 7.4, 16.5 ± 0.2° 2θ and further the peaks at about 9.7, 10.6, 12.5, 14.3, 15.9, 21.3 and 24.8° ± 0.2° 2θ” and process for the preparation thereof. The present invention further provides a Co-crystal of Upadacitinib and Diacetyl- D-tartaric acid characterized in that its X-ray powder diffraction pattern is basically the same as that of FIG.1. In another embodiment, the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 7.9 and 10.3 are absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention. In another embodiment, the present invention provides a compound of Formula-I, which is a Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid, characterized by powder X-ray diffraction pattern (PXRD), wherein the peak at 4.0 is absent in the PXRD of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid in the present invention. The present invention further provides Co-crystal comprises Upadacitinib and Diacetyl-D-tartaric acid within the same crystalline phase in a molar ratio of 1: 0.5. Single Crystal X-ray Diffraction (SCXRD) for Upadacitinib and Diacetyl-D- tartaric acid (1:0.5) co-crystal: SCXRD measurements of the Upadacitinib and Diacetyl-D-tartaric acid crystallized in the monoclinic Crystal system with the C2 Space group and consists of four Upadacitinib molecules with two molecules of Diacetyl-D-tartaric acid (DATA) co-former (1:0.5) in the asymmetric unit as shown below as Figure-1. Fig-1: Displacement ellipsoids are drawn at the 30% probability level and H atoms are shown as small spheres of arbitrary radii. Hydrogen bonds are shown by dashed lines. Table 1. Crystal data and structure refinement for Upadacitinib diacetyl-D-tartaric acid co-crystal. Identification code Upadacitinib diacetyl-D- crystal Empirical formula 2(C17H19F3N6O), C8H10O8 Formula weight 994.92 Temperature 294(2) K Wavelength 0.71073 A Crystal system Monoclinic Space group C2 Unit cell dimensions a = 25.1095(5) A ^o α= 90°. b = 23.3596(5) A ^o β= 108.9710(8)°. c = 20.3721(4) A ^o γ = 90°. Volume 11300.2(4) A ³ Z 8 Density (calculated) 1.170 Mg/m ³ Absorption coefficient 0.098 mm ^-1 F(000) 4144 Crystal size 0.220 x 0.180 x 0.090 mm ³ θ range for data collection 1.057 to 25.000° Index ranges -29<=h<=29, -27<=k<=27, -24<=1<=24 Reflections collected 105460 Independent reflections 19888 [R(int) = 0.0774] Completeness to θ = 25.000° 100.0% Absorption correction Semi-empirical from equivalents Max. and min. transmission 0.7461 and 0.6055 Refinement method Full-matrix least-squares on F ² Data / restraints / parameters 19888 / 159 / 1270 Goodness-of-fit on F ² 1.076 Final R indices [I>26(I)] R1 = 0.1041, wR2 = 0.2558 R indices (all data) R1 = 0.1533, wR2 = 03091 Absolute structure parameter 0.3(3) Extinction coefficient 0.0046(6) Largest diff. peak and hole 0.726 and -0.902 e. A ^{o -3} Measurement Bruker D8 QUEST PHOTON-III Detector Software Used SHELXTL-PLUS Refinement: The X-ray data for Upadacitinib diacetyl-D-tartaric acid was collected at a room temperature on a Bruker D8 QUEST instrument with an IµS Mo microsource (λ=0.7107) and a PHOTON-III detector. The raw data frames were reduced and corrected for absorption effects using Bruker Apex 3 software suite programs. The structure was solved using the intrinsic phasing method and was further refined with the SHELXL program and expanded using Fourier techniques. Anisotropic displacement parameters were included for all non-hydrogen atoms. All N, O, and C bounded H atoms were positioned geometrically and treated as riding on their parent C atoms. The solvent molecules were not identified in different Fourier maps; hence, the squeeze command was applied to remove the solvent contribution to crystal structure. The absolute configuration has been assigned by reference to an unchanged chiral in the synthetic procedure. The hydrogen-bonding interactions in the crystal structure of Upadacitinib diacetyl-D-tartaric acid are shown below in Table-2. Table-3: Hydrogen bonds for Upadacitinib diacetyl-D-tartaric acid co-crystal [A ^o and °]. In another embodiment of the present invention, the co-crystal may be present in crystalline form or amorphous form. More preferably, the co-crystal may be present in crystalline form. The present invention also provides a process for preparing the compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA), comprising the steps of: a) reacting compound of Formula-Va, with compound of Formula-VI in presence of a base in a suitable solvent to produce compound of Formula- XIII. b) cyclizing the compound of Formula-XIII in-situ in presence of Trifluoroacetic anhydride (TFAA) in a suitable solvent to produce compound of Formula-XIV. c) deprotecting the compound of Formula-XIV in-situ in presence of an acid in a suitable solvent followed by treating with (+)-Di-p-toluoyl-D-tartaric Acid (DPTA) in an alcohol solvent to produce compound of Formula-XV. d) reacting the compound of Formula-XV with 2,2,2-trifluoroethanamine or its salt in presence of Carbonyldiimidazole (CDI) and a base in a suitable solvent to produce compound of Formula-XVI. e) deprotecting the compound of Formula-XVI in presence of a base in a suitable solvent followed by treating with p-Toluenesulfonic acid acid to produce compound of Formula-XVII. f) treating the compound of Formula-XVII with Diacetyl-D-Tartaric acid in a suitable solvent followed by adding anti-solvent to produce compound of Formula-I. The base used in Step-a) is an organic or inorganic base. The organic base is selected from N,N-diisopropylamine, N,N-diisopropylethylamine triethylamine, N,N- dimethylamine, trimethylamine, pyridine; the inorganic base is selected from sodium hydride, sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof. preferably sodium hydride. The solvent used in step a) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof preferably dimethylformamide; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The reaction may be performed from -60 ^° C to 60 ^° C for 30 min to 48 hours and then compound of Formula-XIII can be obtained by a usual procedure. The obtained compound-XIII can be used in the next reaction directly without isolation. The solvent used in step b) is an organic solvent, for example an aprotic polar solvent. Appropriate aprotic polar solvents can comprise N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixtures thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. preferably Acetonitrile. The reaction may be performed from 30 ^° C to 90 ^° C for 30 min to 48hours and then compound of Formula-XIV can be obtained by a usual procedure. The obtained compound-XIVcan be used in the next reaction directly without isolation. The acid used in step c) can be an inorganic acid comprising HCl, HBr in water or in organic solvents Methanol, Isopropyl alcohol acetic acid preferably HBr in acetic acid. The solvent used in step c) is an organic solvent, for example an aprotic polar solvent comprises N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, dichloromethane or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, 2-Ethoxyethyl acetate or mixture thereof organic acid comprises Formic acid, Acetic acid Propionic acid or mixture thereof preferably Acetic acid The organic acid used in step c) is selected from tartaric acid, Dibenzoyl-D-tartaric acid, Di-p-toluoyl-D-tartaric acid, Diacetyl-D-tartaric acid or mixture thereof preferably Di-p-toluoyl-D-tartaric acid The reaction may be performed from 0 ^° C to 60 ^° C for 30 min to 48 hours and then compound of Formula-XV can be obtained by a usual procedure. The base used in step d) is selected from triethylamine, N,N-diisopropylamine, N,N- diisopropylethylamine, N,N-dimethylamine, trimethylamine, pyridine or mixture thereof. The solvent used in step d) is an organic solvent, for example an aprotic polar solvent comprises dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, or mixture thereof, preferably dichloromethane; alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert- butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ketone comprises acetone, methylisobutylketone, 2-pentanone, ethylmethylketone, diethylketone; ester comprises ethyl acetate, methyl acetate, butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The reaction may be performed from 0 ^° C to 60 ^° C for 30 min to 48hours and then compound of Formula-XVI can be obtained by a usual procedure. The obtained compound-XVI can be used in the next reaction directly without isolation. The base used in step e) is selected from sodium hydroxide, potassium hydroxide, sodium bicarbonate, potassium bicarbonate, lithium carbonate, sodium carbonate, potassium carbonate, or mixture thereof. The suitable solvent used in step e) is selected from tetrahydrofuran, dichloromethane, N,N-dimethylformamide, dimethylsulfoxide, acetonitrile, water or mixture thereof preferably tetrahydrofuran; The reaction may be performed from 0 ^° C to 60 ^° C for 30 min to 48 hours and then compound of Formula-XVII can be obtained by a usual procedure. The suitable solvent used in step f) is an organic solvent, for example an alcohol comprises methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutylalcohol, tert-butylalcohol, isoamylalcohol, 2-methoxyethanol or mixture thereof; ester comprises ethyl acetate, methyl acetate, n-butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. The anti-solvent used in step f) is selected from ethyl acetate, methyl acetate, n- butyl acetate, isopropyl acetate, methoxy ethyl acetate or mixture thereof. Preferably n-butyl acetate. The reaction may be performed from 0 ^° C to 60 ^° C for 30 min to 48hours and then compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid (DATA). Advantages of present invention: 1. The above reaction scheme is straightforward; minimizes the unit operation, and isolates the intermediate as filterable solid. 2. Controlling of racemization and achieving required chemical and chiral purity. 3. Prepared stable co-crystal with Diacetyl-D-Tartaric acid (DATA). The following examples are provided to illustrate the invention and are merely for illustrative purpose only and should not be construed to limit the scope of the invention. EXAMPLES: EXAMPLE-1: PREPARATION OF (3R,4S)-3-[2-[[(1,1-DIMETHYLETHOXY) CARBONYL][5-[(4-METHYLPHENYL)SULFONYL]-5H-PYRROLO[2,3-b] PYRA-ZIN-2-YL]AMINO]ACETYL]-4-ETHYL-1-PYRROLIDINE CARBOXYLICACID PHENYL METHYL ESTER OF FORMULA-XIII. DMF (1.0 L) was charged and cooled to 0-5°C in a round bottom flask and added sodium hydride (26.1 g, 1.1 m.eq). Compound of Formula-VI (250.0 g, 1.0 m.eq) was added to the above NaH/DMF (1.0 L) mixture over 30-60 mins and stirred for 30 mins. at 0-5°C. The resultant mixture was cooled to -20 to -30°C and added a solution of compound of Formula-Va (250.7 g, 1.1 m.eq in DMF (0.5 L)) over 30-60 mins. The mixture was then agitated for two hrs at -20 to -30°C. The reaction mixture was quenched with a mixture of acetic acid (38.6 g, 1.0 m.eq) and DMF (40 mL) mixture after the reaction was completed by HPLC. The product was extracted with toluene twice (2.5 L, 1.25 L) and the combined organic layers were washed with sodium chloride (1.25 L). The organic layer is concentrated and co-distilled with acetonitrile to get Compound of Formula-XIII as a syrupy mass. The resulted syrupy mass dissolved in acetonitrile (2.5 L) and used for next step. EXAMPLE-2: PREPARATION OF (3S,4R)-3-ETHYL-4-[3-[(4-METHYL PHENYL)SULFONYL]-3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]PYRAZIN-8-YL ]-1- PYRROLIDINE CARBOXYLIC ACID PHENYLMETHYL ESTER OF FORMULA-XIV. To a solution of Compound of Formula-XIII in acetonitrile, trifluoroacetic anhydride (270.3 g, 1.28 moles) was added the mixture was warmed to 70-75°C and stirred for 4 hours. After completing the reaction on seen by HPLC, the mixture was cooled to 65- 70°C and concentrated, yielding a syrupy mass of Compound of Formula-XIV (500ml), which was used for next step without further isolation. EXAMPLE-3: PREPARATION OF 8-[(3R,4S)-4-ETHYL-3-PYRROLIDINYL]-3- [(4-METHYLPHENYL)SULFONYL]-3H-IMIDAZO[1,2-a]PYRROLO[2,3-e] PYRAZINE, (2S,3S)-2,3-BIS[(4-METHYLBENZOYL)OXY]-BUTANEDIOIC ACID (1:0.5) OF FORMULA-XV A solution of Compound of Formula-XIV in acetic acid (832 g, 3.21 moles) was added to HBr in acetic acid (832 g, 3.21 moles) maintain temperature of 0-10°C. The reaction mixture was agitated at 25-30°C for 2 hours, after which the mass was diluted with DM water and washed three times with MTBE (5000 mL). Then the aqueous layer is back- extracted with dichloromethane (2*1250 mL) after pH adjustment by using aqueous ammonia (500 mL) at 0-10°C. The combined organic layers were washed with DM water (1250 mL) and the organic layers were concentrated under reduced pressure. The resulting crude compound was dissolved in methanol (2125 mL), added the Di-p- toluoyl-D-Tartaric acid (136.7g, 0.35 moles) in methanol (2125 mL), and maintained for 30 minutes at 25-30°C followed by 2 hours at 50-55°C. The salt was agitated at 20- 30°C, then 0-5°C and the solid was filtered to yield pure Compound of Formula-XV (198.2g). Yield 51%; HPLC purity is 99.33%, and Chiral HPLC purity is 99.87%. EXAMPLE-04: PREPARATION OF (3S,4R)-3-ETHYL-4-[5-(P-TOLYL SULFONYL)-1,5,7,10-TETRAZATRICYCLO[7.3.0.02,6]DODECA-2(6),3, 7,9, 11-PENTAE-N-12-YL]-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1- CARBOXAMIDE OF FORMULA-XVI. To a cooled 0-5°C suspension of 2,2,2-Trifluoroethylamine hydrochloride (75.73g, 1.5 m.eq) dichloromethane (900 mL), added the CDI (90.8g 1.5 m.eq) followed by triethylamine (56.6 g, 1.5 m.eq). The reaction was maintained at 0-5°C for 2-2.5 hrs, and then added a solution of Formula-XV. After completing the reaction on seen by HPLC, added the pre-cooled DM water (1125 mL, 10°C), mix for 30 minutes, and separate the organic layer with aqueous hydrochloric acid and sodium bicarbonate. Separated the organic layer, concentrated under reduced pressure resulting compound of Formula-XVI as a syrup, and dissolved in THF (2250 ml). Note: Compound of formula-XV free base solution was (225g 1.0 m.eq) was prepared by liberating salt with sodium hydroxide solution (112 mL. 1.5 m.eq) and extracting with Dichloromethane (2250 mL) and used for next step without further isolation. EXAMPLE-05: PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a] PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE, SODIUM P-TOLUENESULFONATE OF FORMULA-XVII. To a solution of compound Formula-XVI in THF (2250 mL) added 50% sodium hydroxide solution (104.52g, 3.5 m.eq) at 25-30°C, maintained the reaction mixture at 50-55°C for 60-75 min, upon completion of the reaction by HPLC, cooled the reaction mixture to 25-30°C and maintained for 3-3.5h at 25-30°C. The precipitated solid was filtered and washed with THF (450 mL), dried under suction to yield compound of Formula-XVII (290g), which was used for next step without any further isolation or purification. EXAMPLE-06: PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2- a]PYRROLO[2,3-e]PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROMETHYL)- PYRROLIDINE-1-CARBOXAMIDE,(+)DIACETYL-D-TARTARICACID (1:0.5) OF FORMULA-I. Compound of Formula-XVII (290g) was added to ethyl acetate (2250 mL) and agitated for 10 minutes before adding DM water (1125 mL) and stirring for another 30 mins. The organic layer was separated, the aqueous layer was successively extracted with Ethyl acetate (1125 mL), and the combined organic layer was washed with sodium bicarbonate solution and DM water (1125 mL). After charcoal treatments concentrated under reduced pressure. Co-distilled twice with Isopropyl alcohol. Thereafter added isopropyl alcohol (337.5 mL), stirred for 15 minutes, then added (+)-Diacetyl-D- tartaric acid (48 g) in n-Butyl acetate (450 mL) solution, stirred for 90 minutes. Thereafter added n-Butyl acetate (10800 mL) agitated for 20-21h, resulting solid was filtered, washed with n-Butyl acetate (450 mL), suction dried under vacuum for 30 min and dried under vacuum to obtain Compound of Formula-I of Co-crystal of Upadacitinib and Diacetyl-D-tartaric acid of Formula-I. Yield: 75%. HPLC purity: 99.97%.